MINIMED™ 780G ADVANCED HYBRID CLOSED-LOOP SYSTEM IN TYPE 1 DIABETES DURING RAMADAN

ADAN: A SINGLE CENTRE EXPERIENCE

Abstract

INTRODUCTION/BACKGROUND
The MiniMed™ 780G automated insulin delivery system has improved outcomes for people with type 1 diabetes. In Putrajaya Hospital, most patients with type 1 diabetes fall in the high-risk category and are advised to avoid fasting during Ramadan, yet many still choose to observe it.

METHODOLOGY
We aim to review the effectiveness and safety of the MiniMed™ 780G use during Ramadan. We report a prospective observational, single-centre study of Type 1 diabetes patients using the MiniMed™ 780G during Ramadan 2024. Four patients were selected and had their CareLink personal data extracted before and during Ramadan to examine safety and glycemic metrics. Changes were made to their pump settings when necessary.

RESULT
All patients were able to fast for more days with the MiniMed™ 780G compared to previous years, with a mean of 13.5 days (8-20 days) on the pump vs 8.3 days (3-12 days) on basal-bolus insulin. All our patients demonstrated hyperglycemia after Iftar which needed 4-5 hours to resolve. Three of 4 patients developed hypoglycemia 1-4 hours before iftar requiring intervention. One patient developed one episode of severe hypoglycemia requiring hospitalization. No patients developed diabetic ketoacidosis. The average TIR was 72% before Ramadan and 70% during Ramadan.

CONCLUSION
The MiniMed™ 780 G increased the number of days of completion in fasting among our patients. However, incidences of hypoglycemia and hyperglycemia persisted requiring adjustments in the pump settings throughout Ramadan. This system allowed our patients to fast confidently and safely. Improvement in the outcome is to be expected with continuous experience in the future.